[HTML][HTML] Applying a biopsychosocial model to migraine: rationale and clinical implications

C Rosignoli, R Ornello, A Onofri, V Caponnetto… - The journal of headache …, 2022 - Springer
Migraine is a complex condition in which genetic predisposition interacts with other
biological and environmental factors determining its course. A hyperresponsive brain cortex …

[HTML][HTML] Exploring novel therapeutic targets in the common pathogenic factors in migraine and neuropathic pain

J Tajti, D Szok, A Csáti, Á Szabó, M Tanaka… - International Journal of …, 2023 - mdpi.com
Migraine and neuropathic pain (NP) are both painful, disabling, chronic conditions which
exhibit some symptom similarities and are thus considered to share a common etiology. The …

Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial

P Pozo-Rosich, J Ailani, M Ashina, PJ Goadsby… - The Lancet, 2023 - thelancet.com
Background In this study, we aimed to evaluate the efficacy, safety, and tolerability of
atogepant for the preventive treatment of chronic migraine. Methods We did this randomised …

[HTML][HTML] Migraine: from pathophysiology to treatment

F Puledda, EM Silva, K Suwanlaong, PJ Goadsby - Journal of Neurology, 2023 - Springer
Migraine is an extremely disabling, common neurological disorder characterized by a
complex neurobiology, involving a series of central and peripheral nervous system areas …

Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: a systematic review and network meta-analysis of phase 3 randomised …

F Haghdoost, F Puledda, D Garcia-Azorin… - …, 2023 - journals.sagepub.com
Background Several novel treatments targeting the calcitonin gene-related peptide pathway
have been developed for migraine. We evaluated the efficacy of these medications …

[HTML][HTML] Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study

CK Cullum, TP Do, M Ashina, L Bendtsen… - The Journal of …, 2022 - Springer
Background Clinical trials have shown that erenumab is effective and well-tolerated for the
preventive treatment of chronic migraine. To extend the results from clinical trials, we …

[HTML][HTML] Migraine symptoms, healthcare resources utilization and disease burden in a large Polish migraine cohort: Results from 'Migraine in Poland'—A nationwide …

M Waliszewska-Prosół, M Straburzyński… - The Journal of …, 2023 - Springer
Abstract Background The Migraine in Poland study is the first large scale nationwide cross-
sectional online survey of symptoms, approaches to management, treatment patterns …

[HTML][HTML] Debate: differences and similarities between tension-type headache and migraine

D Onan, S Younis, WD Wellsgatnik, F Farham… - The journal of headache …, 2023 - Springer
Tension-type headache (TTH) and migraine are two common primary headaches
distinguished by clinical characteristics according to the 3rd edition of the International …

[HTML][HTML] The effect of Lu AG09222 on PACAP38-and VIP-induced vasodilation, heart rate increase, and headache in healthy subjects: An interventional, randomized …

NB Rasmussen, C Deligianni, CE Christensen… - The Journal of …, 2023 - Springer
Background Pituitary adenylate cyclase-activating polypeptide (PACAP), structurally related
to vasoactive intestinal peptide (VIP), is one of the important mediators in the pathogenesis …

[HTML][HTML] The impact of curcumin on migraine: A comprehensive review

H Heidari, M Shojaei, G Askari, M Majeed… - Biomedicine & …, 2023 - Elsevier
Migraine, a neurovascular condition, is a chronic and lifelong disease that affects about 15%
of the population worldwide. Although the exact pathophysiology and etiology of migraine …